Abstract
Antiretroviral therapy with potent combinations of drugs has been responsible for a significant decline in the occurrences of AIDS defining conditions and death in the developed world. However, therapy requires lifelong use and is complicated by relatively high failure rates, significant toxicities, adherence difficulties and the development of resistance. The combination of these complications of therapy and the availability of this treatment to only 1 in 20 of the estimated 34 million people infected world wide has prompted us to reconsider the current strategies for achieving the goals of HIV therapy. A more rational approach to therapeutic interactions is needed, particularly with respect to therapy in the developing world, with the focus shifted towards maintaining relative viral control over the long term. One potential mechanism to attain viral control over the long term is the use of therapeutic vaccines. This chapter will review the scientific rationale for therapeutic HIV-1 vaccines and the vaccines that have been evaluated as a therapeutic to date including recombinant envelope glycoproteins, inactivated envelope depletd virus, regulatory proteins such as Tat, cytokines such as IFN-α, DNA vaccines, and live viral vectors. Although the future role of therapeutic vaccines in the treatment of HIV-1 remains to be determined, at a minimum this immunomodulatory approach will provide new insights into fundamental viral-host cell interactions and the pathogenesis of HIV-1. Yet even more notable, is that, if successful, a therapeutic vaccine product would be inexpensive and rapidly exportable representing a treatment strategy for people living with HIV infection worldwide.
Keywords: hiv, vaccin, therapeutic vaccines, immunotherapy
Current Topics in Medicinal Chemistry
Title: Therapeutic HIV Vaccines
Volume: 3 Issue: 13
Author(s): Bruce L. Gilliam and Robert R. Redfield
Affiliation:
Keywords: hiv, vaccin, therapeutic vaccines, immunotherapy
Abstract: Antiretroviral therapy with potent combinations of drugs has been responsible for a significant decline in the occurrences of AIDS defining conditions and death in the developed world. However, therapy requires lifelong use and is complicated by relatively high failure rates, significant toxicities, adherence difficulties and the development of resistance. The combination of these complications of therapy and the availability of this treatment to only 1 in 20 of the estimated 34 million people infected world wide has prompted us to reconsider the current strategies for achieving the goals of HIV therapy. A more rational approach to therapeutic interactions is needed, particularly with respect to therapy in the developing world, with the focus shifted towards maintaining relative viral control over the long term. One potential mechanism to attain viral control over the long term is the use of therapeutic vaccines. This chapter will review the scientific rationale for therapeutic HIV-1 vaccines and the vaccines that have been evaluated as a therapeutic to date including recombinant envelope glycoproteins, inactivated envelope depletd virus, regulatory proteins such as Tat, cytokines such as IFN-α, DNA vaccines, and live viral vectors. Although the future role of therapeutic vaccines in the treatment of HIV-1 remains to be determined, at a minimum this immunomodulatory approach will provide new insights into fundamental viral-host cell interactions and the pathogenesis of HIV-1. Yet even more notable, is that, if successful, a therapeutic vaccine product would be inexpensive and rapidly exportable representing a treatment strategy for people living with HIV infection worldwide.
Export Options
About this article
Cite this article as:
Gilliam L. Bruce and Redfield R. Robert, Therapeutic HIV Vaccines, Current Topics in Medicinal Chemistry 2003; 3 (13) . https://dx.doi.org/10.2174/1568026033451772
DOI https://dx.doi.org/10.2174/1568026033451772 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plant Proteinases and Inhibitors: An Overview of Biological Function and Pharmacological Activity
Current Protein & Peptide Science How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Chemoresistance in Gynecologic Cancers)
Current Cancer Therapy Reviews The IFN-λ Family (IL-28/29)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in Cancer
Anti-Cancer Agents in Medicinal Chemistry Current Trends in the Use of Cationic Polymer Assemblies for siRNA and Plasmid DNA Delivery
Pharmaceutical Nanotechnology Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Drug Loaded Erythrocytes: As Novel Drug Delivery System
Current Pharmaceutical Design Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain
Current Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Recent Progress in Chemically Modified siRNAs
Mini-Reviews in Medicinal Chemistry Viral Vector-Mediated Gene Therapy for Hemophilia
Current Gene Therapy Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy